Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex

Objective: To determine whether alternating regimens consisting of zidovudine and 2',3'-dideoxycytidine (ddC) reduce the toxicity and maintain or increase the antiretroviral effect associated with each drug alone. Design: An unblinded, randomized (phase 11) clinical trial in which seven treatment regimens were compared. Setting: Outpatient clinics of 12 AIDS Clinical Trials Units. Patients: One hundred thirthy-one patients with the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex and serum p24 antigenemia (≥70 pg/mL)